FULC vs. MELI

Last updated Jun 4, 2026

FULC (Fulcrum Therapeutics, Inc.) and MELI (MercadoLibre, Inc.) are both stocks. FULC operates in Biotechnology (Healthcare), while MELI operates in Internet Retail (Consumer Cyclical). Over the past 5 years, FULC returned -18.10%/yr vs 4.33%/yr for MELI. At a 0.25 correlation, their price movements are largely independent.

Performance

FULC vs. MELI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Fulcrum Therapeutics, Inc. (FULC) and MercadoLibre, Inc. (MELI). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, FULC achieves a -71.53% return, which is significantly lower than MELI's -18.65% return.

FULC

• 1D: 2.55%
• 1M: -54.13%
• YTD: -71.53%
• 6M: -64.46%
• 1Y: -54.23%
• 3Y*: 1.60%
• 5Y*: -18.10%
• 10Y*: —

MELI

• 1D: -2.05%
• 1M: -9.65%
• YTD: -18.65%
• 6M: -22.70%
• 1Y: -37.03%
• 3Y*: 8.84%
• 5Y*: 4.33%
• 10Y*: 28.35%

*Multi-year figures are annualized to reflect compound growth (CAGR)

FULC vs. MELI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
FULC Fulcrum Therapeutics, Inc.	-71.53%	140.64%	-30.37%	-7.28%	-58.85%	51.07%	-29.63%	23.26%
MELI MercadoLibre, Inc.	-18.65%	18.46%	8.20%	85.71%	-37.24%	-19.51%	192.90%	-11.83%

Correlation

The correlation between FULC and MELI is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.16
Correlation (3Y) Calculated over the trailing 3-year period	0.22
Correlation (5Y) Calculated over the trailing 5-year period	0.26
Correlation (All Time) Calculated using the full available price history since Jul 19, 2019	0.25

Fundamentals

Market Cap FULC : $245.41M MELI : $83.07B
EPS FULC : -$1.15 MELI : $37.87
PB Ratio FULC : 0.74 MELI : 11.41
Total Revenue (TTM) FULC : $0.00 MELI : $30.67B
Gross Profit (TTM) FULC : $0.00 MELI : $13.95B
EBITDA (TTM) FULC : -$78.37M MELI : $3.11B

Return for Risk

FULC vs. MELI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

FULC

FULC Risk / Return Rank: 16
FULC Sharpe Ratio Rank: 18
FULC Sortino Ratio Rank: 23
FULC Omega Ratio Rank: 22
FULC Calmar Ratio Rank: 16
FULC Martin Ratio Rank: 2

MELI

MELI Risk / Return Rank: 6
MELI Sharpe Ratio Rank: 6
MELI Sortino Ratio Rank: 8
MELI Omega Ratio Rank: 8
MELI Calmar Ratio Rank: 5
MELI Martin Ratio Rank: 3

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

FULC vs. MELI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Fulcrum Therapeutics, Inc. (FULC) and MercadoLibre, Inc. (MELI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	FULC	MELI	Difference
Sharpe ratio Return per unit of total volatility	-0.55	-0.94	+0.39
Sortino ratio Return per unit of downside risk	-0.34	-1.23	+0.89
Omega ratio Gain probability vs. loss probability	0.95	0.84	+0.11
Calmar ratio Return relative to maximum drawdown	-0.69	-0.91	+0.22
Martin ratio Return relative to average drawdown	-1.81	-1.66	-0.15
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

FULC vs. MELI - Sharpe Ratio Comparison

The current FULC Sharpe Ratio is -0.55, which is higher than the MELI Sharpe Ratio of -0.94. The chart below compares the historical Sharpe Ratios of FULC and MELI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	FULC	MELI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.55	-0.94	+0.39
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.16	0.09	-0.25
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.58	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.17	0.45	-0.61

Drawdowns

FULC vs. MELI - Drawdown Comparison

The maximum FULC drawdown since its inception was -92.70%, roughly equal to the maximum MELI drawdown of -89.49%. Use the drawdown chart below to compare losses from any high point for FULC and MELI.

Drawdown Indicators

	FULC	MELI	Difference
Max Drawdown Largest peak-to-trough decline	-92.70%	-89.49%	-3.21%
Max Drawdown (1Y) Largest decline over 1 year	-78.49%	-40.82%	-37.67%
Max Drawdown (3Y) Largest decline over 3 years	-79.08%	-40.82%	-38.26%
Max Drawdown (5Y) Largest decline over 5 years	-92.70%	-68.64%	-24.06%
Max Drawdown (10Y) Largest decline over 10 years	—	-69.12%	—
Current Drawdown Current decline from peak	-89.60%	-37.31%	-52.29%
Average Drawdown Average peak-to-trough decline	-62.65%	-23.57%	-39.08%
Ulcer Index Depth and duration of drawdowns from previous peaks	30.01%	22.40%	+7.61%

Volatility

FULC vs. MELI - Volatility Comparison

Fulcrum Therapeutics, Inc. (FULC) has a higher volatility of 73.43% compared to MercadoLibre, Inc. (MELI) at 17.25%. This indicates that FULC's price experiences larger fluctuations and is considered to be riskier than MELI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	FULC	MELI	Difference
Volatility (1M) Calculated over the trailing 1-month period	73.43%	17.25%	+56.18%
Volatility (6M) Calculated over the trailing 6-month period	95.79%	30.23%	+65.56%
Volatility (1Y) Calculated over the trailing 1-year period	99.47%	39.50%	+59.97%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	111.24%	49.68%	+61.56%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	111.94%	48.88%	+63.06%

Dividends

FULC vs. MELI - Dividend Comparison

Neither FULC nor MELI has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
FULC Fulcrum Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
MELI MercadoLibre, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.19%	0.38%	0.36%

Financials

Frequently Asked Questions

Can I hold both FULC and MELI in my portfolio?

FULC and MELI have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, FULC or MELI?

FULC has higher volatility (73.43%) compared to MELI (17.25%). In terms of maximum drawdown, FULC dropped -92.70% vs MELI's -89.49%.

Which has better risk-adjusted returns?

FULC currently has the higher Sharpe Ratio (-0.55 vs -0.94), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.